1. The Hatch-Waxman Framework: Statute, Economics, and IP Valuation The Legislative Architecture The Drug Price Competition and Patent Term Restoration […]
Information contained in expired drug patents can be invaluable to researchers developing new products, but caution is required to avoid legal problems.
A comprehensive analysis for pharma IP teams, portfolio managers, payer strategy leads, and institutional investors examining the structural economics, IP
The global generic drugs market was valued at $468.08 billion in 2025 and is projected to reach $728.64 billion by
An evidence-based analysis of FDA-approved oncology drug economics, patent strategy, and what the numbers actually mean for payers, investors, and
Cancer Drug ROI: Why Pharma Makes $14.50 for Every $1 Spent on R&D Read Post »
Recent successful drug launches indicate a trend toward more specialized, high-priced drugs that treat less-common medical conditions.
Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.
1. Why This Matters Now Rare disease drugs now account for 52% of all new molecular entities (NMEs) approved by
Orphan Drug Reform: How Mark Cuban’s Cost-Plus Model Is Forcing a Reckoning Read Post »
The cost of bringing a drug to market has crossed $2 billion. The Phase 2 failure rate sits near 60%.
AI Drug Discovery’s $110B Productivity Bet: What the Clinical Data Actually Shows Read Post »
Sign in or create a free account to read this DrugPatentWatch article
